Ensoma Appoints Jon Garen as Chief Corporate Development and Business Officer
Slice of Healthcare Team
10/30/2024
Key Highlights
- Jon Garen joins Ensoma as Chief Corporate Development and Business Officer
- Garen’s experience spans genomic medicines, oncology, and rare diseases
- First IND submission expected next year for pioneering in vivo HSC-targeted gene therapy
- Garen’s background includes strategic roles at Dunad Therapeutics, Nocion Therapeutics, and uniQure
Source: Business Wire
Notable Quotes
“ Jon is an accomplished leader with an exceptional track record in genetic medicines and business development… as we prepare for our first IND submission next year—representing the first in vivo HSC-targeted gene therapy in humans. ”
Jim Burns, CEO at Ensoma
“ The potential of Ensoma’s in vivo platform to revolutionize genetic treatments ”
and potential cures for patients and their families – is truly exciting.” — Jon Garen, Chief Corporate Development and Business Officer at Ensoma
